Related Experiment Video

Updated: Oct 15, 2026

Analyzing the Permeability of the Blood-Brain Barrier by Microbial Traversal through Microvascular Endothelial Cells
06:26

Analyzing the Permeability of the Blood-Brain Barrier by Microbial Traversal through Microvascular Endothelial Cells

Published on: February 14, 2020

The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation

M E Cooper1, V Thallas, J Forbes

  • 1Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, West Heidelberg, Australia.

Diabetologia
|June 16, 2000
PubMed
Abstract

Insights

N-phenacylthiazolium bromide, a cross-link breaker, prevents advanced glycation end-product accumulation in diabetic blood vessels. Early treatment with this compound also attenuates vascular hypertrophy, offering potential for diabetic complication management.

Area of Science:

  • Vascular Biology
  • Diabetic Complications
  • Pharmacology

Background:

  • Advanced glycation end products (AGEs) are implicated in diabetic vascular complications.
  • Thiazolium compounds, like N-phenacylthiazolium bromide, can cleave preformed AGEs.

Purpose of the Study:

  • To investigate the effect of N-phenacylthiazolium bromide on vascular AGE accumulation and hypertrophy in diabetic rats.
  • To explore the therapeutic potential of AGE cross-link breakers in managing diabetic vascular disease.

Main Methods:

  • Control and streptozotocin-induced diabetic rats were treated with N-phenacylthiazolium bromide (10 mg/kg) for 3 or 6 weeks.
  • Vascular AGE accumulation was assessed using radioimmunoassay and immunohistochemistry.
  • Mesenteric vascular hypertrophy was measured to evaluate treatment efficacy.

Main Results:

  • Diabetes significantly increased mesenteric vascular AGEs.
  • N-phenacylthiazolium bromide treatment prevented AGE accumulation.
  • Vascular hypertrophy was attenuated by early N-phenacylthiazolium bromide intervention.

Conclusions:

  • AGE cross-link breakers are effective in preventing and potentially reversing vascular AGE accumulation.
  • Early intervention with N-phenacylthiazolium bromide shows promise in mitigating diabetic vascular hypertrophy.
  • These findings suggest a potential role for AGE cross-link breakers in treating diabetic vascular complications.

More Related Videos

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

Related Concept Videos

Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
β-Dicarbonyl Compounds via Crossed Claisen Condensations01:18

β-Dicarbonyl Compounds via Crossed Claisen Condensations

Crossed Claisen condensations are base-promoted reactions between two different ester molecules producing β-dicarbonyl compounds. The reaction involving esters, with both containing α hydrogen, results in a mixture of four different products that are difficult to isolate. This reduces the synthetic utility of the reaction.
Radical Chain-Growth Polymerization: Mechanism01:09

Radical Chain-Growth Polymerization: Mechanism

The radical chain-growth polymerization mechanism consists of three steps: initiation, propagation, and termination of polymerization. The polymerization initiates when a free radical generated from the radical initiator adds to the unsaturated bond in the monomer. The unpaired electron of the free radical and one π electron in the unsaturated bond creates a σ bond between the free radical and the monomer. As a result, the other π electron in the unsaturated bond converts this species into the...
Cationic Chain-Growth Polymerization: Mechanism00:57

Cationic Chain-Growth Polymerization: Mechanism

The cationic polymerization mechanism consists of three steps: initiation, propagation, and termination. In the initiation step of the polymerization process, the π bond of a monomer gets protonated by the Lewis acid catalyst, which is formed from boron trifluoride and water. The protonation of the π bond generates a carbocation stabilized by the electron‐donating group. In the propagation step, the π bond of the second monomer acts as a nucleophile and attacks the generated carbocation,...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...